RT Journal Article
SR Electronic
T1 The efficacy of multiple use of interferon-γ inducer in treatment of recurrent acute respiratory viral infections in children with bronchial asthma
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1155
VO 42
IS Suppl 57
A1 Elena Kondiurina
A1 Tatiana Elkina
A1 Vera Zelenskaya
A1 Natalia Timinskaia
A1 Maria Shably
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P1155.abstract
AB Background: Recurrent episodes of acute respiratory viral infections (ARVI) are common for children with bronchial asthma (BA). The opportunities of multiple use of interferon-gamma inducer (IFN-i) containing release active antibodies to IFN-gamma (anaferon) are unknown.Aim: To evaluate the efficacy of IFN-i in treatment of recurrent ARVI in children with BA.Methods: A comparative, randomized, double-blind placebo-controlled trial of IFN-i efficacy in treatment of recurrent ARVI in 200 children of 1-5 years with virus-induced phenotype of mild and moderate BA. 100 patients of the 1st group received IFN-i in preventive regimen and 100 patients of the 2nd group took placebo in the same way. In case of appearing ARVI symptoms the patients received IFN-i/placebo in treatment regimen and symptomatic medicines. The duration of the 1st and 2nd episodes of ARVI in groups were estimated.Results: During 3-months follow-up period 20 patients of the 1st group and 36 children of the 2nd group had recurrent ARVI (40 and 76 cases, respectively). The mean duration of the 2nd episode of the ARVI was 5,2±0,5 days (vs 5,7±0,4 of the 1st episode) in the 1st group and 9,1±0,8 days (vs 9,4±0,6 respectively) in the 2nd group. The duration of the each episodes of the virus-induced exacerbation of BA in both groups was comparable.Conclusions: The use of IFN-i (anaferon) in the treatment of the recurrent ARVI leads to reduction of the disease duration. Multiple administration of IFN-i doesn’t influence on its curative efficacy and duration of the virus-induced exacerbation of BA.